Accepted_test

Search for possible molecular targets of new anti-tuberculosis compounds

Authors:
Kalitvanskaya M.A., Volgograd Medical University, 400066 Volgograd, pl. Fallen fighters, 1
Makarov D.A., Engelhardt Institute of Molecular Biology RAS, 119991, Moscow, st. Vavilova, 32
Khandazhinskaya A.L., Engelhardt Institute of Molecular Biology RAS, 119991, Moscow, st. Vavilova, 32
Anashkina A. A, Engelhardt Institute of Molecular Biology RAS, 119991, Moscow, st. Vavilova, 32; Sechenov University, 119048, Moscow, st. Trubetskaya, 8.

Abstract ID: 629

Event: BGRS-abstracts

Sections: [Sym 3] Section “Pharmacology cheminformatics and chemical biology”

The urgency of developing new anti-tuberculosis drugs is associated with the spread of M. tuberculosis strains resistant to existing drugs. In addition, the molecular mechanisms of action of anti-tuberculosis drugs are unknown. In this work, based on existing anti-tuberculosis drugs, we screened structurally similar compounds and studied their possible interaction with a number of M. tuberculosis proteins. It was found that 1-(1,4-dihydroxy-1H-benzo[d]imidazol-2-yl)-5-(piperidin-1-yl)pyrimidin-2,4(1H,3H)-dione presumably interacts with proteins 6-hydroxymethyl-7,8-dihydropteroate synthase, isocitrate lyase 3-dehydroquinate dehydratase. These results require further experimental verification.